Eliquis is a prescription medication marketed under the brand name Eliquis and contains the active anticoagulant Apixaban. It is supplied as a solid pill in two strengths: 2.5 mg and 5 mg. Eliquis belongs to the therapeutic class of Heart & Blood Pressure agents, specifically the direct Factor Xa inhibitors used to reduce the risk of blood clots. In Hong Kong, Eliquis is regulated by the Department of Health under the Medicines and Poisons Ordinance and is available only with a medical prescription.
Apixaban blocks the activity of Factor Xa, a key enzyme in the coagulation cascade that converts prothrombin to thrombin. By inhibiting this step, Eliquis reduces the formation of fibrin, the protein mesh that stabilizes blood clots.
Apixaban is absorbed rapidly from the gastrointestinal tract, achieving an oral bioavailability of roughly 50 %. It is metabolized primarily by CYP3A4 and excreted through both renal (≈27 %) and fecal pathways. This balanced elimination profile allows use in patients with mild to moderate kidney impairment, though dose adjustments may be required for severe renal dysfunction.
Eliquis is approved by regulatory agencies-including the U.S. FDA, the European EMA, and the Hong Kong Department of Health-for the following indications:
These indications are supported by large, randomized clinical trials such as ARISTOTLE (AF) and AMPLIFY (VTE treatment). Eliquis is typically prescribed for adults; age-related dose considerations are addressed in the dosing section.
Some clinicians prescribe Apixaban for conditions that are not officially approved, based on emerging evidence:
Disclaimer: Off-label use must be guided by a qualified healthcare professional who evaluates the individual’s risk-benefit profile.
If any of the above conditions apply, discussion with a healthcare provider is essential before initiating therapy.
Most of these events are mild and resolve without intervention.
Note: Patients should disclose all prescription drugs, over-the-counter medicines, herbal supplements, and vitamins to the prescriber.
This article provides educational information about Eliquis and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes only and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes. Eliquis tablets are allowed in both checked and carry-on baggage. Keep them in their original prescription label and a copy of the prescribing doctor’s note, as some countries may request documentation for anticoagulant medications.
Eliquis does not interfere with standard chemistry or hematology panels, but it prolongs coagulation assays such as PT/INR and aPTT. Inform the laboratory that you are taking apixaban so they can interpret results appropriately.
In Hong Kong, the 5 mg tablet is round, white, and imprinted with “E-5”. The 2.5 mg tablet is round, white, and imprinted with “E-2.5”. In other regions the imprint may differ; always verify by checking the packaging.
Standard workplace drug screens target substances of abuse and typically do not detect anticoagulants like apixaban. However, specialized testing can identify it if specifically requested.
Occasional short-term use of low-dose ibuprofen may increase bleeding risk, especially in patients with other risk factors. Discuss any NSAID use with your prescriber to weigh benefits against potential bleeding.
Eliquis provides similar stroke-prevention efficacy without the need for routine INR monitoring, and it has fewer dietary restrictions. Warfarin, however, remains an option for patients with severe kidney disease where apixaban is contraindicated.
Transition protocols vary. Generally, Eliquis can be started once the INR is ≤ 2.0 on warfarin, but an individualized plan from your clinician is essential to avoid gaps in anticoagulation.
Take the missed dose as soon as you remember if it is more than 6 hours before the next scheduled dose. Otherwise, skip the missed dose and continue with your regular dosing schedule. Do not double the dose.
Store Eliquis in a cool, dry place away from direct sunlight and high temperatures. Do not leave the bottle in a car or near heat-producing appliances. If the medication has been exposed to extreme heat, replace it with a new supply.
Brand-name Eliquis includes costs related to research, development, and regulatory approval. Generic versions may become available after patent expiration, often leading to lower prices. Pricing can vary by pharmacy and insurance coverage; always verify with your local provider.
